BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 15272576)

  • 1. [Biomarker in gynecologic malignancies].
    Isonishi S
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1003-7. PubMed ID: 15272576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum tumor markers.
    Perkins GL; Slater ED; Sanders GK; Prichard JG
    Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical usefulness of tumor markers for the diagnosis of ovarian cancer].
    Ito K; Udagawa Y; Nozawa S
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):1964-70. PubMed ID: 1417005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experiences with the cancer marker CA 125 in gynecologic diseases].
    Pilgrim G; von Broen B; Johannsmeyer KD
    Z Gesamte Inn Med; 1989 Apr; 44(8):251-4. PubMed ID: 2741520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic significance of tumor markers for gynecologic malignancies].
    Aoki D; Hirasawa A; Susumu N
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):411-6. PubMed ID: 15791829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor markers in epithelial ovarian cancer].
    Di Cocco B; Calabretta F; Alghisi F; Salesi N; Bossone G
    Minerva Ginecol; 2003 Aug; 55(4):327-32. PubMed ID: 14581857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The diagnostic value of the assay of lactate dehydrogenese combined with other tumor markers in ovarian cancer].
    Tang BJ; Li L; Xu J
    Zhonghua Fu Chan Ke Za Zhi; 1994 Jun; 29(6):336-9, 381. PubMed ID: 8001406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of some tumor markers in differential diagnosis of ovarian tumor.
    Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
    Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.
    Erkanli A; Taylor DD; Dean D; Eksir F; Egger D; Geyer J; Nelson BH; Stone B; Fritsche HA; Roden RB
    Cancer Res; 2006 Feb; 66(3):1792-8. PubMed ID: 16452240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined use of tumor markers and MRI tomography in differential diagnosis of ovarian neoplasms].
    Pavlov SB; Akulina EA; Pavlova GB
    Klin Med (Mosk); 1999; 77(4):49-51. PubMed ID: 10356919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 72.4, SCC, 90 K].
    Garzetti GC; Di Lauro RM; Ciavattini A; Pallotta MR; Marchegiani F; Valensise H; Tranquilli AL; Arduini D; Romanini C
    Ann Ostet Ginecol Med Perinat; 1991; 112(5):320-3. PubMed ID: 1817444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and application of protein biomarkers for ovarian cancer.
    Gagnon A; Ye B
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):9-13. PubMed ID: 18196999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A clinical evaluation of the CA 72-4 serum level as a possible tumor marker].
    Jibiki K; Takeda M; Abe H; Ito M; Odagiri E; Demura R; Demura H; Takizawa K
    Gan No Rinsho; 1990 Oct; 36(12):2146-52. PubMed ID: 2232183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation of serum CA-50 and CA 19-9 in gynecological tumors].
    Suzuki M; Ohwada M; Tamada T; Sakurabayashi I; Kawai T
    Rinsho Byori; 1989 Jul; 37(7):784-8. PubMed ID: 2558243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of serum biomarkers for detection of early-stage ovarian cancer.
    Nosov V; Su F; Amneus M; Birrer M; Robins T; Kotlerman J; Reddy S; Farias-Eisner R
    Am J Obstet Gynecol; 2009 Jun; 200(6):639.e1-5. PubMed ID: 19285648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of monoclonal antibody OC 125 in gynecological oncology].
    Wu AR; Wang EY; Wang XX; Jia XH; Li L
    Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening and detection of ovarian cancer.
    Breedlove G; Busenhart C
    J Midwifery Womens Health; 2005; 50(1):51-4. PubMed ID: 15637515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of galactosyltransferase associated with tumor (GAT), a new tumor marker for ovarian cancer--with special reference to the discrimination between ovarian cancer and endometriosis].
    Nozawa S; Udagawa Y; Ito K; Nishimura H; Yakushiji M; Shiota M; Noda K; Yajima M; Ohkura H; Murae M
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):507-16. PubMed ID: 8129392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tumor markers in gynecologic malignancies].
    Tojo S; Suzuki A; Fujii S; Ashitaka Y; Maruo T; Matsuura S
    Gan No Rinsho; 1983 May; 29(6):678-83. PubMed ID: 6192268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.